Press Release Archive

Allergan's BOTOX -- Botulinum Toxin Type A -- Not the Cause of Botulism in Florida Patients  

Allergan Update Regarding Florida Facility Investigation; Company Urges Physicians to Use Only FDA-Approved and U.S. Licensed Botulinum Toxin Products to Protect Public Health  

Allergan Update Regarding Florida Facility Reports; No Safety Concerns Found with Any BOTOX -R- Manufacturing Lots  

Allergan Statement Regarding Florida Facility Reports  

Allergan Statement Regarding Florida Reports  

Allergan Reports Third Quarter Operating Results; Pharmaceutical Sales Increased 15 Percent for the Third Quarter; Board of Directors Declares Third Quarter Dividend  

Jury Rules in Favor of Allergan, Inc.; Judge Dismisses Remaining Claims  

Allergan Announces Agreement to Discontinue Peplin Collaboration  

Allergan Announces Quarterly Conference Call  

Allergan Receives Action Letter for Oral Tazarotene  

Allergan Files Suit Against Alcon for Patent Infringement  

Allergan Receives Approvable Letter for LUMIGAN -- bimatoprost-timolol  

Allergan Announces New Executive Vice President, Research & Development; Scott Whitcup, M.D. to lead Allergan's Worldwide R&D Efforts  

Allergan Announces New Board Member; Prof. Trevor M. Jones Appointed  

Allergan Reports Second Quarter Operating Results  

FDA Approves BOTOX -- Botulinum Toxin Type A -- for Treatment of Severe Underarm Sweating; New Approval Marks Fourth Therapeutic Indication for Allergan's BOTOX Over Last 15 Years  

Allergan Announces Conference Call to Discuss FDA Advisory Committee Meeting on Oral Tazarotene  

Allergan Announces Retirement of Board Member Ronald M. Cresswell  

Allergan Announces Quarterly Conference Call  

Allergan, Inc. Wins $1.5 Million BOTOX ® Trademark Infringement And Unfair Competition Case Against Mira Life Group, Inc.